The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

  • This share is currently suspended. It was suspended at a price of 5.375

Share Price Information for Iconic Labs (ICON)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.375
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 5.375
ICON Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Changes & Business and Strategy Update

4 Jan 2024 07:00

RNS Number : 5879Y
Iconic Labs PLC
04 January 2024
 

4 January 2024

 

Iconic Labs PLC

 

("Iconic" or the "Company")

 

Board Changes

 

Business and Strategy Update

 

Iconic Labs PLC (LSE: ICON), is pleased to announce the appointment of Victor Humberdot and Bela Lendvai-Lintner as Non-executive Directors to the Board of Iconic, as well as an update on the business and strategy of the Company.

 

Board Changes

 

Victor Humberdot and Bela Lendvai-Lintner have been appointed as Non-executive Directors with immediate effect and will replace Marija Hrebac, David Stybr and Emmanuel Blouin who have stepped down from the Board.

 

Victor Humberdot (aged 34) is an experienced investment banker. Having started his career at BBVA and Kepler Cheuvreux, he then joined the investment fund of Société Générale, Private Banking in Luxembourg before, most recently, being responsible for the external growth of an investment holding company in the construction sector before being M&A Manager at Exponens Corporate Finance and more recently a Vice President at the corporate finance boutique, DDA & Company in Paris. He is currently Founder and CEO of HUVI Capital, his own investment holding company. Victor holds a master's degree in international finance from Neoma Business School and a master's in physics and mechanical engineering from Le Havre Normandy University.

 

Bela Lendvai-Lintner (aged 48) has more than 20 years of experience in private equity within a wide range of industry sectors. He started his career at KPMG in corporate finance focused on M&A transactions. Bela has also held multiple roles at ARX Equity Partners, an independent Central Europe-focused mid-market buyout firm and is currently a Partner and Investment Committee Member. He holds a Bachelor of Science in Business Administration/Finance from Ohio State University.

 

Business and Strategy Update

 

In conjunction with these Board changes, Iconic is also focusing on its strategy. Earlier in 2023, Iconic intended to establish a strategic advisory services business, engaging in fee-based service contracts with technology companies. The objective was to provide valuable guidance on growth plans, product development, marketing and capital raising.

 

However, following the successful Company restructuring, and its exit from administration, Iconic is now channelling all its efforts towards identifying a suitable acquisition target, most likely in the form of a reverse takeover ("RTO") target. Whilst the Company continues to narrow down the pool of viable acquisition candidates, in parallel, Iconic will continue to develop, with its strategic partners, its sole asset, Gay Star News, an online media platform dedicated to the LGBTQ+ community.

 

Iconic is confident that this strategic shift will pave the way for long-term growth and create substantial value for its shareholders.

 

Brad Taylor, Chief Executive Officer of Iconic Labs PLC, commented:

 

"I would like to extend my gratitude to Marija, Emmanuel and David for their unwavering support and guidance in navigating us through the complex restructuring of the Company with an exceptionally high level of professionalism and skill.

 

"As the Company pivots to focus all efforts on acquiring a suitable company through an RTO, I welcome Victor and Bela to the Board and look forward to working closely with them, who between them bring a blend of finance and industry experience to the Board which will prove invaluable in achieving our strategic objective of fostering long-term growth and value for all our shareholders."

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

Additional Information

 

Bela Lendvai-Lintner is currently or has been Director or Partner of the following companies and/or firms in the last five years:

 

Current Directorships

 

Accounting Partners Hungary Kft

XMobile International Kft

Pannon Provider Zrt

Beer=Win Holding Kft

Orenthal Kft

 

Previous Directorships

 

Gomba Invest Kft

 

Victor Humberdot is currently or has been Director or Partner of the following companies or firms in the last five years:

 

Current Directorships

 

HUVI Capital

IPAHUMA

 

Previous Directorships

 

Quickcool AB

 

For any further information or enquiries please contact:

 

Iconic Labs

Brad Taylor, Chief Executive Officer

Tel: +44 (0) 7462 156238

ir@iconiclabs.co.uk

Novum Securities Limited

David Coffman / Daniel Harris

 Tel: +44 (0) 20 7399 9400

 

Yellow Jersey PR

Sarah Hollins

Annabelle Wills

Bessie Elliot

 

 Tel: +44 (0) 20 3004 9512

 iconic@yellowjerseypr.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAFFDEDELEAA
Date   Source Headline
1st May 20187:02 amRNSAnnual Accounts and Fundraising Update
26th Mar 20187:00 amRNSLandmark deal to launch CellPlan insurance in Asia
19th Mar 20187:00 amRNSGranted Innovate UK KTP for Stem Cell Research
27th Feb 20187:00 amRNSLicence Award from the Human Tissue Authority
19th Feb 20187:00 amRNSBoard Changes and Launch of Wideacademy Platform
21st Dec 20177:00 amRNSCorporate Update
2nd Nov 20177:00 amRNSRevenue generation with White Apex agreement
12th Oct 20177:00 amRNSCellPlan expansion, e-commerce platform launch UK
11th Oct 20177:00 amRNSPartner Secured to Expand into MENA & Asia-Pacific
29th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSWideacademy Update, Presenting at Investor Event
15th Aug 20177:00 amRNSRaises £750,000 to support Company's divisions
31st Jul 20177:00 amRNSResearch Licence Granted from HTA
24th Jul 20177:00 amRNSNew product to target the dental market
21st Jul 20177:00 amRNSCellPlan launches E-Commerce Platform in the UK
12th Jul 20177:00 amRNSCorporate Charity Commitment
4th Jul 20177:00 amRNSAgreement to Roll Out CellPlan in Brazil
3rd Jul 20177:00 amRNSInvestor Evening and CFO Now Employed Full-time
27th Jun 20177:00 amRNSRevenue with launch of CellPlan
22nd Jun 20173:30 pmRNSResults of AGM
22nd Jun 20177:00 amRNSAGM Statement and Notice of Investor Evening
12th Jun 20177:00 amRNSWideAcademy Strategic Update
6th Jun 20177:00 amRNSLaunch of CellPlan set to generate maiden revenues
2nd Jun 20177:00 amRNSWideCells Named 21st in Global DISRUPT 100 List
23rd May 20177:00 amRNSAttendance at British Dental Conference
15th May 20177:00 amRNSAttendance at Brazilian Conference
4th May 20172:15 pmRNSHolding(s) in Company
2nd May 20177:40 amRNSPosting of Report and Accounts and Notice of AGM
12th Apr 20171:00 pmRNSPlacing
30th Mar 20177:00 amRNSPreliminary Results
16th Feb 20177:00 amRNSBoard Appointment
31st Jan 20177:00 amRNSDirector Purchases and Grant of Options
30th Jan 20174:40 pmRNSSecond Price Monitoring Extn
30th Jan 20174:35 pmRNSPrice Monitoring Extension
26th Jan 201710:30 amRNSGrant of Options
24th Jan 20177:00 amRNSExtends CellPlan Roll Out & New Product Launch
9th Jan 20177:00 amRNSDefinitive Agreement with BioVault for CellPlan
30th Nov 20167:00 amRNSNew Revenue Stream: Stem Cell Research, Manchester
7th Nov 20167:00 amRNSLOI with 1st Cord Blood Bank to Roll Out CellPlan
24th Oct 20167:00 amRNSCorporate Update
10th Oct 20167:00 amRNSUpdate on CellPlan
27th Sep 20167:00 amRNSPartners with University of Westminster
5th Sep 20167:00 amRNSLaunches WideCells Brasil
12th Aug 20167:00 amRNSHoldings In Company
5th Aug 20167:00 amRNSUpdate on Manchester Facility and Appointments
27th Jul 20168:00 amRNSPlacing & First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.